MX2019011324A - Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano. - Google Patents

Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.

Info

Publication number
MX2019011324A
MX2019011324A MX2019011324A MX2019011324A MX2019011324A MX 2019011324 A MX2019011324 A MX 2019011324A MX 2019011324 A MX2019011324 A MX 2019011324A MX 2019011324 A MX2019011324 A MX 2019011324A MX 2019011324 A MX2019011324 A MX 2019011324A
Authority
MX
Mexico
Prior art keywords
papilloma virus
human papilloma
associated disease
cxcr7
cxcr4
Prior art date
Application number
MX2019011324A
Other languages
English (en)
Inventor
Poznansky Mark
Gelfand Jeffrey
Pai Sara
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2019011324A publication Critical patent/MX2019011324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a métodos y composiciones para tratar enfermedades asociadas al virus del papiloma humano (VPH) usando un inhibidor de la señalización de CXCL12; la invención se refiere además a métodos y composiciones para tratar enfermedades resistentes al bloqueo del punto de control inmune utilizando un inhibidor de la señalización de CXCL12; la invención se refiere además a métodos y composiciones para mejorar la respuesta inmune contra una enfermedad asociada al VPH usando un inhibidor de la señalización de CXCL12.
MX2019011324A 2017-03-23 2018-03-22 Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano. MX2019011324A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475497P 2017-03-23 2017-03-23
US201762503988P 2017-05-10 2017-05-10
PCT/US2018/023689 WO2018175676A1 (en) 2017-03-23 2018-03-22 Cxcr4/cxcr7 blockade and treatment of human papilloma virus-associated disease

Publications (1)

Publication Number Publication Date
MX2019011324A true MX2019011324A (es) 2020-01-21

Family

ID=63586596

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011324A MX2019011324A (es) 2017-03-23 2018-03-22 Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.

Country Status (5)

Country Link
US (2) US11547694B2 (es)
EP (1) EP3600395A4 (es)
JP (1) JP2020515542A (es)
MX (1) MX2019011324A (es)
WO (1) WO2018175676A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013063A (es) 2020-04-24 2022-12-08 Genexine Inc Metodo para tratamiento del cancer cervicouterino.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5272082A (en) 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
CA3052445C (en) 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
CA2586765A1 (en) 2004-11-05 2006-12-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
EP1988927B1 (en) 2006-02-02 2016-04-13 The General Hospital Corporation Engineered antibody-stress protein fusions
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
PT3214091T (pt) 2010-12-09 2019-01-11 Univ Pennsylvania Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
CN104379179A (zh) 2012-04-11 2015-02-25 美国卫生和人力服务部 靶向b-细胞成熟抗原的嵌合抗原受体
US20140065096A1 (en) 2012-09-05 2014-03-06 Regen BioPharma, Inc. Cancer therapy by ex vivo activated autologous immune cells
CA2886859C (en) 2012-10-02 2022-05-17 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
LT3283107T (lt) * 2015-04-17 2020-09-10 Bristol-Myers Squibb Company Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją
MX2017015811A (es) 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白

Also Published As

Publication number Publication date
WO2018175676A1 (en) 2018-09-27
US11547694B2 (en) 2023-01-10
US20230149347A1 (en) 2023-05-18
EP3600395A1 (en) 2020-02-05
US20200030286A1 (en) 2020-01-30
EP3600395A4 (en) 2021-05-05
JP2020515542A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2019012233A (es) Anticuerpos anti-sirpa.
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MD4733C1 (ro) Anticorpi anti-TIGIT
MX2022007522A (es) Anticuerpos anti-cd27.
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
MY184076A (en) Hpv chimaeric particle
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201071316A1 (ru) Иммуномодуляция ингибиторами ингибиторов апоптоза
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
MX356745B (es) Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
EA201791525A2 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MX2019011324A (es) Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX2020007050A (es) Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.
WO2018236086A3 (ko) 신규한 에로모나스 하이드로필라 박테리오파지 Aer-HYP-2 및 이의 에로모나스 하이드로필라 균 증식 억제 용도
MX2022002478A (es) Proteinas de union a cr2 y su uso en tratamientos medicos.
WO2016036252A3 (en) Hepatitis c virus specific antibody